{"id":"piperazine","rwe":[{"pmid":"41903477","year":"2026","title":"Design and synthesis of novel piperazine-based sulfamate derivatives as steroid sulfatase inhibitors.","finding":"","journal":"Bioorganic chemistry","studyType":"Clinical Study"},{"pmid":"41901360","year":"2026","title":"Rational Design, Synthesis, and Systematic Evaluation of Redox-Responsive SN-38 Prodrugs for Selective Activation in Hypoxic Tumor Microenvironments.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41869942","year":"2026","title":"Enhanced Stability and Release Efficiency of an Emulsion Drag Reducer Using a pH-Responsive Rigid Piperazine Ring Gemini Surfactant.","finding":"","journal":"Langmuir : the ACS journal of surfaces and colloids","studyType":"Clinical Study"},{"pmid":"41855831","year":"2026","title":"Design and synthesis of fluorescent calix[4]arene-1,8-Naphthalimide derivatives: Transparent biofilms, antioxidant and antimicrobial properties, and real-samples applications.","finding":"","journal":"Food chemistry","studyType":"Clinical Study"},{"pmid":"41851339","year":"2026","title":"Bicarbonate buffer enhances functional sperm selection compared to Zwitterionic buffers in sperm preparation.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"}],"tags":[{"label":"piperazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P02CB01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Ascariasis","category":"indication"},{"label":"Enterobiasis","category":"indication"},{"label":"Bluline","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antinematodal Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Disease of liver","Epilepsy","Kidney disease"]},"trials":[],"aliases":[],"company":"Bluline","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PIPERAZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:16:28.992468+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:16:34.226939+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIPERAZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:16:34.682940+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1412/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:35.801725+00:00"}},"allNames":"antiren","offLabel":[],"synonyms":["piperazine phosphate hydrate","piperazine phosphate","piperazine","antiren","eraverm","pipersol","1,4-piperazine","piperazine citrate","multifuge","piperazine sulfate","dipiperazine sulfate","dipiperazine","piperazine dihydrochloride","piperazine monohydrochloride","piperazine-carbon disulfide complex"],"timeline":[{"date":"1954-07-12","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bluline)"}],"aiSummary":"Antiren (Piperazine) is a small molecule drug in the piperazine class, originally developed and currently owned by BLULINE. It was FDA approved in 1954 for the treatment of Ascariasis and Enterobiasis. As an off-patent medication, Antiren is available as a generic product from multiple manufacturers. Key safety considerations include the potential for gastrointestinal side effects. Antiren is a commercially available medication for the treatment of parasitic worm infections.","approvals":[{"date":"1954-07-12","orphan":false,"company":"BLULINE","regulator":"FDA"}],"brandName":"Antiren","ecosystem":[{"indication":"Ascariasis","otherDrugs":[{"name":"levamisole","slug":"levamisole","company":""},{"name":"mebendazole","slug":"mebendazole","company":""},{"name":"thiabendazole","slug":"thiabendazole","company":""}],"globalPrevalence":null},{"indication":"Enterobiasis","otherDrugs":[{"name":"mebendazole","slug":"mebendazole","company":""},{"name":"thiabendazole","slug":"thiabendazole","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"piperazine","explanation":"","oneSentence":"","technicalDetail":"Antiren exerts its effects by inhibiting the nicotinic acetylcholine receptors in the muscles of the parasitic worms, leading to muscle paralysis and eventual expulsion from the body."},"commercial":{"launchDate":"1954","_launchSource":"DrugCentral (FDA 1954-07-12, BLULINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2188","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PIPERAZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIPERAZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:20:51.611425","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:37.507229+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"diethylcarbamazine","drugSlug":"diethylcarbamazine","fdaApproval":"1950-11-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"piperazine","indications":{"approved":[{"name":"Ascariasis","source":"DrugCentral","snomedId":2435008,"regulator":"FDA"},{"name":"Enterobiasis","source":"DrugCentral","snomedId":266162007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"diethylcarbamazine","brandName":"diethylcarbamazine","genericName":"diethylcarbamazine","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04771520","phase":"PHASE2","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-20","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Locally Advanced Malignant Solid Neoplasm","Locally Advanced Melanoma","Locally Advanced Primary Malignant Central Nervous System Neoplasm","Locally Advanced Sarcoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Primary Malignant Central Nervous System Neoplasm","Metastatic Sarcoma","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT05377242","phase":"NA","title":"Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-05-31","conditions":["Gulf War Illness"],"enrollment":390,"completionDate":"2026-06-30"},{"nctId":"NCT03539731","phase":"PHASE1","title":"[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers","status":"TERMINATED","sponsor":"Guido A. Davidzon, MD, SM","startDate":"2018-04-23","conditions":["Healthy Subject","Intracranial Neoplasm","Glioblastoma"],"enrollment":27,"completionDate":"2022-12-31"},{"nctId":"NCT01837862","phase":"PHASE1,PHASE2","title":"A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas","status":"COMPLETED","sponsor":"Julie Krystal","startDate":"2013-10-22","conditions":["Pilomyxoid Astrocytoma","Pilocytic Astrocytoma","Glioma, Astrocytic","Optic Nerve Glioma","Pleomorphic Xanthoastrocytoma","Glioblastoma Multiforme","Anaplastic Astrocytoma","Gliosarcoma","Diffuse Intrinsic Pontine Glioma","DIPG","Low-grade Glioma","Brainstem Glioma"],"enrollment":36,"completionDate":"2024-04"},{"nctId":"NCT03757403","phase":"PHASE2","title":"RDD1609 as a Treatment for Idiopathic Pruritus Ani","status":"WITHDRAWN","sponsor":"RDD Pharma Ltd","startDate":"2020-05-01","conditions":["Idiopathic Pruritus Ani"],"enrollment":0,"completionDate":"2020-12-31"},{"nctId":"NCT02644291","phase":"PHASE1","title":"Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-05","conditions":["Medulloblastoma","Astrocytoma, Grade III","Glioblastoma","Anaplastic Astrocytoma","Brain Stem Neoplasms, Malignant","Oligodendroblastoma","Anaplastic Oligodendroglioma","Malignant Glioma"],"enrollment":16,"completionDate":"2022-06-09"},{"nctId":"NCT01729260","phase":"PHASE1","title":"Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-04-04","conditions":["Newly Diagnosed High-Grade Glioma"],"enrollment":24,"completionDate":"2021-04-16"},{"nctId":"NCT01905423","phase":"","title":"Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-05","conditions":["Lymphatic Filariasis","Soil Transmitted Helminth Infections"],"enrollment":17108,"completionDate":"2015-12"},{"nctId":"NCT03962829","phase":"NA","title":"Effect of mCPP on Cognitive Control, Appetite, and Neural Responses","status":"TERMINATED","sponsor":"University of Birmingham","startDate":"2019-02-01","conditions":["Eating Behavior","Obesity"],"enrollment":32,"completionDate":"2020-03-20"},{"nctId":"NCT03261596","phase":"PHASE4","title":"Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana","status":"WITHDRAWN","sponsor":"PATH","startDate":"2017-09","conditions":["Hookworm Infections"],"enrollment":0,"completionDate":"2017-12"},{"nctId":"NCT00000314","phase":"PHASE2","title":"M-CPP and Fenfluramine in Cocaine Addicts - 3","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1994-09","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":"1999-08"},{"nctId":"NCT02034162","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12","conditions":["Helminth Infections"],"enrollment":295,"completionDate":"2015-09"},{"nctId":"NCT01314937","phase":"PHASE4","title":"The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2011-09","conditions":["Malnutrition","Intestinal Diseases, Parasitic"],"enrollment":1760,"completionDate":"2013-07"},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":["Vomiting"],"enrollment":50,"completionDate":"2007-03"},{"nctId":"NCT02051738","phase":"PHASE1","title":"A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":["Healthy"],"enrollment":1,"completionDate":"2014-04"},{"nctId":"NCT01173562","phase":"PHASE3","title":"A Safety Study of Mebendazole in Children 2 to 10 Years of Age","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-02","conditions":["Healthy Volunteers"],"enrollment":397,"completionDate":"2010-03"},{"nctId":"NCT01297530","phase":"PHASE1","title":"Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Bayer","startDate":"2011-04","conditions":["Neoplasms"],"enrollment":5,"completionDate":"2012-07"},{"nctId":"NCT00735774","phase":"PHASE1","title":"Suitability of 11C-ORM-13070 as a PET Tracer","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2008-08","conditions":["Healthy"],"enrollment":18,"completionDate":"2009-05"},{"nctId":"NCT00000312","phase":"PHASE1","title":"Alterations in Serotonergic Functions in Cocaine Addicts - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"5408","NDDF":"002977","UNII":"1RTM4PAL0V","CHEBI":"CHEBI:28568","VANDF":"4018854","RXNORM":"1549138","UMLSCUI":"C0031957","chemblId":"CHEMBL1412","ChEMBL_ID":"CHEMBL1412","KEGG_DRUG":"D00807","DRUGBANK_ID":"DB00592","PDB_CHEM_ID":" PZE","PUBCHEM_CID":"4837","SNOMEDCT_US":"26109001","SECONDARY_CAS_RN":"18534-18-4","MESH_DESCRIPTOR_UI":"D000077489","MESH_SUPPLEMENTAL_RECORD_UI":"C006589"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1954-","companyName":"Bluline","relationship":"Original Developer"}],"publicationCount":8649,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P02CB01","allCodes":["P02CB01"]},"biosimilarFilings":[],"originalDeveloper":"Bluline","recentPublications":[{"date":"2026 Mar 19","pmid":"41903477","title":"Design and synthesis of novel piperazine-based sulfamate derivatives as steroid sulfatase inhibitors.","journal":"Bioorganic chemistry"},{"date":"2026 Mar 21","pmid":"41901360","title":"Rational Design, Synthesis, and Systematic Evaluation of Redox-Responsive SN-38 Prodrugs for Selective Activation in Hypoxic Tumor Microenvironments.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 23","pmid":"41869942","title":"Enhanced Stability and Release Efficiency of an Emulsion Drag Reducer Using a pH-Responsive Rigid Piperazine Ring Gemini Surfactant.","journal":"Langmuir : the ACS journal of surfaces and colloids"},{"date":"2026 Mar 11","pmid":"41855831","title":"Design and synthesis of fluorescent calix[4]arene-1,8-Naphthalimide derivatives: Transparent biofilms, antioxidant and antimicrobial properties, and real-samples applications.","journal":"Food chemistry"},{"date":"2026 Mar 18","pmid":"41851339","title":"Bicarbonate buffer enhances functional sperm selection compared to Zwitterionic buffers in sperm preparation.","journal":"Scientific reports"}],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Alpharma Us Pharms","Impax Labs","Lannett","Luitpold","Solvay"],"status":"withdrawn","companyName":"Bluline","companyId":"bluline","modality":"Small molecule","firstApprovalDate":"1954","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1954-07-12T00:00:00.000Z","mah":"BLULINE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:37.507229+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}